NASDAQ:CLBS - Caladrius Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.05 +0.04 (+1.00 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$4.05
Today's Range$4.00 - $4.05
52-Week Range$2.63 - $6.35
Volume9,921 shs
Average Volume18,757 shs
Market Capitalization$38.38 million
P/E Ratio-2.28
Dividend YieldN/A
Beta1.25

About Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences logoCaladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.

Receive CLBS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLBS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLBS
CUSIPN/A
Phone908-842-0100

Debt

Debt-to-Equity RatioN/A
Current Ratio6.86
Quick Ratio6.86

Price-To-Earnings

Trailing P/E Ratio-2.28
Forward P/E Ratio-1.76
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.28 million
Price / Sales1.10
Cash FlowN/A
Price / CashN/A
Book Value$4.73 per share
Price / Book0.86

Profitability

EPS (Most Recent Fiscal Year)($1.78)
Net Income$22.97 million
Net MarginsN/A
Return on Equity-39.28%
Return on Assets-30.61%

Miscellaneous

Employees22
Outstanding Shares9,570,000

Caladrius Biosciences (NASDAQ:CLBS) Frequently Asked Questions

What is Caladrius Biosciences' stock symbol?

Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences Inc (NASDAQ:CLBS) released its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.52) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.80) by $0.28. View Caladrius Biosciences' Earnings History.

When is Caladrius Biosciences' next earnings date?

Caladrius Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Caladrius Biosciences.

What price target have analysts set for CLBS?

2 brokerages have issued 1-year price targets for Caladrius Biosciences' shares. Their forecasts range from $7.00 to $12.00. On average, they anticipate Caladrius Biosciences' share price to reach $9.50 in the next year. View Analyst Ratings for Caladrius Biosciences.

Who are some of Caladrius Biosciences' key competitors?

Who are Caladrius Biosciences' key executives?

Caladrius Biosciences' management team includes the folowing people:
  • David J. Mazzo Ph.D., Chief Executive Officer, Independent Director (Age 59)
  • Joseph Talamo, Chief Financial Officer, Senior Vice President (Age 47)
  • Douglas W. Losordo M.D., Chief Medical Officer (Age 58)
  • Gregory B. Brown M.D., Director (Age 64)
  • Richard J. Berman J.D., Independent Director (Age 75)
  • Drew Bernstein CPA., , Independent Director (Age 59)
  • Martyn D. Greenacre, Independent Director (Age 75)
  • Steven Mark Klosk, Independent Director (Age 60)

Has Caladrius Biosciences been receiving favorable news coverage?

News stories about CLBS stock have trended positive recently, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Caladrius Biosciences earned a media sentiment score of 0.26 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.11 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Caladrius Biosciences' major shareholders?

Caladrius Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (0.35%) and JPMorgan Chase & Co. (0.20%). View Institutional Ownership Trends for Caladrius Biosciences.

Which major investors are buying Caladrius Biosciences stock?

CLBS stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP and JPMorgan Chase & Co.. View Insider Buying and Selling for Caladrius Biosciences.

How do I buy shares of Caladrius Biosciences?

Shares of CLBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Caladrius Biosciences' stock price today?

One share of CLBS stock can currently be purchased for approximately $4.05.

How big of a company is Caladrius Biosciences?

Caladrius Biosciences has a market capitalization of $38.38 million and generates $35.28 million in revenue each year. The biotechnology company earns $22.97 million in net income (profit) each year or ($1.78) on an earnings per share basis. Caladrius Biosciences employs 22 workers across the globe.

How can I contact Caladrius Biosciences?

Caladrius Biosciences' mailing address is 106 ALLEN ROAD FOURTH FLOOR, BASKING RIDGE NJ, 07920. The biotechnology company can be reached via phone at 908-842-0100 or via email at [email protected]


MarketBeat Community Rating for Caladrius Biosciences (CLBS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  215 (Vote Outperform)
Underperform Votes:  150 (Vote Underperform)
Total Votes:  365
MarketBeat's community ratings are surveys of what our community members think about Caladrius Biosciences and other stocks. Vote "Outperform" if you believe CLBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLBS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Caladrius Biosciences (NASDAQ:CLBS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Caladrius Biosciences in the last 12 months. Their average twelve-month price target is $9.50, suggesting that the stock has a possible upside of 134.57%. The high price target for CLBS is $12.00 and the low price target for CLBS is $7.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.50$9.50$7.00$7.00
Price Target Upside: 134.57% upside55.99% upside72.41% upside123.64% upside

Caladrius Biosciences (NASDAQ:CLBS) Consensus Price Target History

Price Target History for Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences (NASDAQ:CLBS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2018HC WainwrightReiterated RatingBuy$12.00MediumView Rating Details
3/23/2018Chardan CapitalBoost Price TargetBuy ➝ Buy$6.50 ➝ $7.00HighView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Caladrius Biosciences (NASDAQ:CLBS) Earnings History and Estimates Chart

Earnings by Quarter for Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences (NASDAQ:CLBS) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.3 EPS
Next Year EPS Consensus Estimate: $-2.43 EPS

Caladrius Biosciences (NASDAQ CLBS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018($0.71)N/AView Earnings Details
5/10/2018Q1 2018($0.80)($0.5210)ViewN/AView Earnings Details
3/22/2018n/a($0.70)($0.40)ViewListenView Earnings Details
11/9/2017Q3 2017($0.79)($0.38)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.96)($0.88)ViewN/AView Earnings Details
5/18/2017Q1 2017($0.72)($1.1160)$9.50 million$7.92 millionViewN/AView Earnings Details
3/17/2017Q4 2016($0.80)($0.73)$6.30 million$10.18 millionViewN/AView Earnings Details
11/7/2016Q3($1.55)($1.09)$7.70 million$9.32 millionViewListenView Earnings Details
8/9/2016Q216($1.75)($1.33)$7.53 million$8.30 millionViewN/AView Earnings Details
5/5/2016Q1 2016($0.80)($2.10)$10.40 million$7.49 millionViewN/AView Earnings Details
3/15/2016Q4($0.28)($0.59)$7.67 million$7.60 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.30)($0.21)$6.00 million$5.89 millionViewN/AView Earnings Details
8/6/2015Q215($0.32)($0.31)$5.20 million$5.87 millionViewN/AView Earnings Details
5/5/2015Q1 2015($4.60)($4.80)$4.50 million$3.17 millionViewN/AView Earnings Details
3/2/2015Q4 2014($4.90)($4.40)$5.20 million$5.28 millionViewN/AView Earnings Details
10/30/2014Q3 2014($0.41)($0.44)$4.00 million$4.12 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.28)($0.38)$4.70 million$4.49 millionViewN/AView Earnings Details
5/8/2014Q1 2014($3.30)$4.06 millionViewN/AView Earnings Details
3/13/2014Q4 2013($4.70)$4.08 millionViewN/AView Earnings Details
11/7/2013Q3 2013($4.50)$3.71 millionViewN/AView Earnings Details
8/8/2013Q2 2013($4.60)$4.36 millionViewN/AView Earnings Details
5/9/2013Q1 2013($5.00)($5.00)$4.20 million$2.52 millionViewN/AView Earnings Details
11/14/2012Q312($0.05)($0.06)$3.50 million$4.40 millionViewN/AView Earnings Details
8/14/2012Q2 2012($5.40)ViewN/AView Earnings Details
5/11/2012Q1 2012($6.80)ViewN/AView Earnings Details
3/20/2012Q4 2011($7.00)$1.20ViewN/AView Earnings Details
11/11/2011Q3 2011($12.00)($8.00)ViewN/AView Earnings Details
8/15/2011Q2 2011($9.00)($13.40)ViewN/AView Earnings Details
11/12/2010Q3 2010($10.00)($12.60)ViewN/AView Earnings Details
8/16/2010Q2 2010($7.00)($11.10)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Caladrius Biosciences (NASDAQ:CLBS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Caladrius Biosciences (NASDAQ CLBS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.50%
Institutional Ownership Percentage: 7.80%
Insider Trading History for Caladrius Biosciences (NASDAQ:CLBS)
Insider Trading History for Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences (NASDAQ CLBS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/7/2017Eric WeiDirectorSell6,575$4.77$31,362.75View SEC Filing  
2/6/2017Eric WeiDirectorSell8,425$4.61$38,839.25View SEC Filing  
7/1/2016Eric WeiDirectorSell87,500$0.60$52,500.00View SEC Filing  
6/24/2016Eric WeiDirectorSell22,698$0.55$12,483.90View SEC Filing  
8/17/2015David J MazzoCEOBuy20,000$1.40$28,000.00View SEC Filing  
8/11/2015Robert S VatersCFOBuy81,000$1.24$100,440.00View SEC Filing  
12/9/2014Steven S MyersDirectorBuy20,000$3.56$71,200.00View SEC Filing  
12/8/2014Rimasia Capital Partners ManagDirectorSell16,060$3.75$60,225.00View SEC Filing  
12/3/2014Rimasia Capital Partners ManagDirectorSell12,000$4.01$48,120.00View SEC Filing  
12/1/2014Steven S MyersDirectorBuy10,000$3.92$39,200.00View SEC Filing  
11/25/2014Steven M KloskDirectorBuy10,000$3.99$39,900.00View SEC Filing  
11/24/2014Andrew L PecoraInsiderBuy12,500$4.01$50,125.00View SEC Filing  
11/24/2014Steven S MyersDirectorBuy19,800$3.94$78,012.00View SEC Filing  
12/12/2013Richard BermanDirectorSell12,218$5.99$73,185.82View SEC Filing  
12/9/2013Rimasia Capital Partners Managmajor shareholderSell12,530$6.37$79,816.10View SEC Filing  
12/28/2012Richard J BermanDirectorSell149,306$0.59$88,090.54View SEC Filing  
9/18/2012Richard J BermanDirectorSell36,000$0.69$24,840.00View SEC Filing  
9/17/2012Rimasia Capital Partners ManagMajor ShareholderSell30,000$0.71$21,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Caladrius Biosciences (NASDAQ CLBS) News Headlines

Source:
DateHeadline
Zacks: Brokerages Anticipate Caladrius Biosciences Inc (CLBS) Will Announce Earnings of -$0.57 Per ShareZacks: Brokerages Anticipate Caladrius Biosciences Inc (CLBS) Will Announce Earnings of -$0.57 Per Share
www.americanbankingnews.com - May 26 at 9:12 PM
Caladrius Biosciences (CLBS) Stock Rating Lowered by Zacks Investment ResearchCaladrius Biosciences (CLBS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 15 at 8:15 PM
Financial Contrast: Caladrius Biosciences (CLBS) & DaVita (DVA)Financial Contrast: Caladrius Biosciences (CLBS) & DaVita (DVA)
www.americanbankingnews.com - May 15 at 5:21 PM
HC Wainwright Reiterates "Buy" Rating for Caladrius Biosciences (CLBS)HC Wainwright Reiterates "Buy" Rating for Caladrius Biosciences (CLBS)
www.americanbankingnews.com - May 11 at 7:05 PM
Caladrius Biosciences (CLBS) Releases  Earnings Results, Beats Estimates By $0.28 EPSCaladrius Biosciences (CLBS) Releases Earnings Results, Beats Estimates By $0.28 EPS
www.americanbankingnews.com - May 11 at 5:41 PM
Caladrius Biosciences (CLBS) CEO David Mazzo on Q1 2018 Results - Earnings Call TranscriptCaladrius Biosciences' (CLBS) CEO David Mazzo on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 9:16 AM
Caladrius Biosciences beats by $0.15Caladrius Biosciences beats by $0.15
seekingalpha.com - May 10 at 5:22 PM
Caladrius Biosciences Reports 2018 First Quarter Financial ResultsCaladrius Biosciences Reports 2018 First Quarter Financial Results
finance.yahoo.com - May 10 at 5:22 PM
For Diabetes Patients, Management Solutions Are As Critical As MedicationsFor Diabetes Patients, Management Solutions Are As Critical As Medications
finance.yahoo.com - May 10 at 5:22 PM
Zacks: Analysts Anticipate Caladrius Biosciences (CLBS) Will Announce Earnings of -$0.82 Per ShareZacks: Analysts Anticipate Caladrius Biosciences (CLBS) Will Announce Earnings of -$0.82 Per Share
www.americanbankingnews.com - May 9 at 9:14 PM
Caladrius Biosciences (CLBS) Scheduled to Post Earnings on WednesdayCaladrius Biosciences (CLBS) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - May 9 at 1:50 AM
Caladrius Biosciences (CLBS) Downgraded by Zacks Investment Research to SellCaladrius Biosciences (CLBS) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - May 8 at 8:04 PM
Caladrius Biosciences (CLBS) and Davita (DVA) Financial SurveyCaladrius Biosciences (CLBS) and Davita (DVA) Financial Survey
www.americanbankingnews.com - May 8 at 1:31 PM
Caladrius Biosciences to Participate at the 15th International Symposium on Cardiovascular Regeneration and RepairCaladrius Biosciences to Participate at the 15th International Symposium on Cardiovascular Regeneration and Repair
finance.yahoo.com - May 7 at 9:22 AM
Caladrius Biosciences (CLBS) Raised to "Hold" at ValuEngineCaladrius Biosciences (CLBS) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - May 3 at 10:19 PM
Caladrius Biosciences to Host First Quarter 2018 Financial Results Conference Call on Thursday, May 10, 2018 at 4:30 p.m. Eastern TimeCaladrius Biosciences to Host First Quarter 2018 Financial Results Conference Call on Thursday, May 10, 2018 at 4:30 p.m. Eastern Time
finance.yahoo.com - May 3 at 8:31 AM
Caladrius Biosciences (CLBS) Upgraded by Zacks Investment Research to "Hold"Caladrius Biosciences (CLBS) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - May 2 at 10:58 PM
Caladrius Biosciences (CLBS) versus Fresenius Medical Care (FMS) Head-To-Head ReviewCaladrius Biosciences (CLBS) versus Fresenius Medical Care (FMS) Head-To-Head Review
www.americanbankingnews.com - May 2 at 5:24 AM
Critical Comparison: Caladrius Biosciences (CLBS) & Davita (DVA)Critical Comparison: Caladrius Biosciences (CLBS) & Davita (DVA)
www.americanbankingnews.com - April 28 at 11:28 PM
Comparing Caladrius Biosciences (CLBS) and Fresenius Medical Care (FMS)Comparing Caladrius Biosciences (CLBS) and Fresenius Medical Care (FMS)
www.americanbankingnews.com - April 26 at 11:16 PM
 Analysts Expect Caladrius Biosciences (CLBS) Will Post Earnings of -$0.82 Per Share Analysts Expect Caladrius Biosciences (CLBS) Will Post Earnings of -$0.82 Per Share
www.americanbankingnews.com - April 22 at 11:15 AM
Wired News - Mesoblast Announced Updated Data from Phase-3 and Phase-2b Clinical Trials of MPC-150-IM in Patients with Chronic Heart FailureWired News - Mesoblast Announced Updated Data from Phase-3 and Phase-2b Clinical Trials of MPC-150-IM in Patients with Chronic Heart Failure
finance.yahoo.com - April 20 at 8:24 AM
Fresenius Medical Care (FMS) & Caladrius Biosciences (CLBS) Financial SurveyFresenius Medical Care (FMS) & Caladrius Biosciences (CLBS) Financial Survey
www.americanbankingnews.com - April 16 at 7:17 AM
Comparing Tivity Health (TVTY) & Caladrius Biosciences (CLBS)Comparing Tivity Health (TVTY) & Caladrius Biosciences (CLBS)
www.americanbankingnews.com - April 15 at 9:27 AM
Caladrius Biosciences (CLBS) vs. Fresenius Medical Care (FMS) Critical SurveyCaladrius Biosciences (CLBS) vs. Fresenius Medical Care (FMS) Critical Survey
www.americanbankingnews.com - April 13 at 11:55 PM
Caladrius Bios CLBS12 nabs accelerated review status in Japan for critical limb ischemiaCaladrius Bio's CLBS12 nabs accelerated review status in Japan for critical limb ischemia
seekingalpha.com - April 10 at 5:22 PM
Caladrius Biosciences Receives SAKIGAKE Expedited Review Designation in Japan for CLBS12 for Treating Critical Limb IschemiaCaladrius Biosciences Receives SAKIGAKE Expedited Review Designation in Japan for CLBS12 for Treating Critical Limb Ischemia
finance.yahoo.com - April 10 at 8:20 AM
Caladrius Biosciences to Participate at Upcoming April ConferencesCaladrius Biosciences to Participate at Upcoming April Conferences
finance.yahoo.com - April 9 at 5:25 PM
Caladrius Biosciences (CLBS) Rating Lowered to Sell at Zacks Investment ResearchCaladrius Biosciences (CLBS) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 6 at 8:10 PM
-$0.82 EPS Expected for Caladrius Biosciences (CLBS) This Quarter-$0.82 EPS Expected for Caladrius Biosciences (CLBS) This Quarter
www.americanbankingnews.com - April 5 at 1:12 PM
Caladrius Biosciences to Present at The MicroCap ConferenceCaladrius Biosciences to Present at The MicroCap Conference
finance.yahoo.com - April 3 at 8:13 AM
Head-To-Head Comparison: Caladrius Biosciences (CLBS) vs. American Renal Associates (ARA)Head-To-Head Comparison: Caladrius Biosciences (CLBS) vs. American Renal Associates (ARA)
www.americanbankingnews.com - April 2 at 7:52 AM
Contrasting Caladrius Biosciences (CLBS) & Catasys (CATS)Contrasting Caladrius Biosciences (CLBS) & Catasys (CATS)
www.americanbankingnews.com - April 1 at 9:22 PM
Catasys (CATS) & Caladrius Biosciences (CLBS) Critical ReviewCatasys (CATS) & Caladrius Biosciences (CLBS) Critical Review
www.americanbankingnews.com - April 1 at 9:20 PM
Caladrius Biosciences (CLBS) CEO David Mazzo on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaCaladrius Biosciences' (CLBS) CEO David Mazzo on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 24 at 8:29 AM
Chardan Capital Increases Caladrius Biosciences (CLBS) Price Target to $7.00Chardan Capital Increases Caladrius Biosciences (CLBS) Price Target to $7.00
www.americanbankingnews.com - March 23 at 4:00 PM
Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results - GlobeNewswire (press release)Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results - GlobeNewswire (press release)
globenewswire.com - March 23 at 8:21 AM
Caladrius Biosciences (CLBS) Releases Quarterly  Earnings Results, Beats Expectations By $0.29 EPSCaladrius Biosciences (CLBS) Releases Quarterly Earnings Results, Beats Expectations By $0.29 EPS
www.americanbankingnews.com - March 23 at 7:52 AM
 Analysts Expect Caladrius Biosciences Inc (CLBS) Will Post Earnings of -$0.83 Per Share Analysts Expect Caladrius Biosciences Inc (CLBS) Will Post Earnings of -$0.83 Per Share
www.americanbankingnews.com - March 19 at 1:54 PM
Caladrius Biosciences to Host Fourth Quarter and Year End 2017 Financial Results Conference Call on Thursday ... - NasdaqCaladrius Biosciences to Host Fourth Quarter and Year End 2017 Financial Results Conference Call on Thursday ... - Nasdaq
www.nasdaq.com - March 17 at 9:22 AM
Caladrius Biosciences to Host Fourth Quarter and Year End 2017 Financial Results Conference Call on Thursday, March 22, 2018 at 4:30 p.m. Eastern TimeCaladrius Biosciences to Host Fourth Quarter and Year End 2017 Financial Results Conference Call on Thursday, March 22, 2018 at 4:30 p.m. Eastern Time
finance.yahoo.com - March 15 at 9:38 AM
Caladrius Biosciences (CLBS) Reports Dosing of 1st Patient with CLBS12 in Phase 2 Critical Limb Ischemia Trial in JapanCaladrius Biosciences (CLBS) Reports Dosing of 1st Patient with CLBS12 in Phase 2 Critical Limb Ischemia Trial in Japan
www.streetinsider.com - March 13 at 9:53 AM
Caladrius Biosciences Doses First Patient with CLBS12 in Phase 2 Critical Limb Ischemia Trial in JapanCaladrius Biosciences Doses First Patient with CLBS12 in Phase 2 Critical Limb Ischemia Trial in Japan
finance.yahoo.com - March 13 at 9:53 AM
Caladrius Biosciences to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium - GlobeNewswire (press release)Caladrius Biosciences to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium - GlobeNewswire (press release)
globenewswire.com - March 9 at 5:38 PM
Caladrius Biosciences to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering SymposiumCaladrius Biosciences to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
finance.yahoo.com - March 8 at 5:25 PM
Caladrius Biosciences (CLBS) Announces Interim Analysis for Phase 2 T-Rex Trial of CLBS03 for Type 1 Diabetes - StreetInsider.comCaladrius Biosciences (CLBS) Announces Interim Analysis for Phase 2 T-Rex Trial of CLBS03 for Type 1 Diabetes - StreetInsider.com
www.streetinsider.com - March 8 at 9:32 AM
Caladrius Biosciences Reports Interim Analysis for Phase 2 T-Rex Trial of CLBS03 for Type 1 DiabetesCaladrius Biosciences Reports Interim Analysis for Phase 2 T-Rex Trial of CLBS03 for Type 1 Diabetes
finance.yahoo.com - March 8 at 9:32 AM
Caladrius Biosciences (CLBS) Set to Announce Quarterly Earnings on ThursdayCaladrius Biosciences (CLBS) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - March 8 at 1:11 AM
Caladrius Biosciences (CLBS) Given a $7.00 Price Target by HC Wainwright AnalystsCaladrius Biosciences (CLBS) Given a $7.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 6 at 8:04 PM
Here’s Why Caladrius Biosciences Inc (CLBS) Shares Are Skyrocketing TodayHere’s Why Caladrius Biosciences Inc (CLBS) Shares Are Skyrocketing Today
finance.yahoo.com - March 6 at 5:16 PM

SEC Filings

Caladrius Biosciences (NASDAQ:CLBS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Caladrius Biosciences (NASDAQ:CLBS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Caladrius Biosciences (NASDAQ CLBS) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.